These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26053647)

  • 21. The metrics of change: the impact of the FDA's pending LDT regulation.
    Lazarus TS; Chaihorsky L
    MLO Med Lab Obs; 2014 Dec; 46(12):28-9. PubMed ID: 25622449
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA perspectives on pharmacogenetic testing.
    Harper CC; Philip R; Robinowitz M; Gutman SI
    Expert Rev Mol Diagn; 2005 Sep; 5(5):643-8. PubMed ID: 16149867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science.
    Sharfstein J
    JAMA; 2015 Feb; 313(7):667-8. PubMed ID: 25560381
    [No Abstract]   [Full Text] [Related]  

  • 24. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tighter gene tests.
    Fox J
    Nat Biotechnol; 2008 Jul; 26(7):721. PubMed ID: 18612277
    [No Abstract]   [Full Text] [Related]  

  • 26. How will the FDA impact the laboratory developed test?
    Davis J; Wentz J
    Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories.
    Higgs J; Gambhir N; Ramsden SC; Poulton K; Newman WG
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):121-5. PubMed ID: 20039783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Providing patients with information on pharmacogenetic testing.
    Fleeman N; Dickson R
    Nurs Stand; 2009 Jan 28-Feb 3; 23(21):46-8. PubMed ID: 19248450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New administration, continuing challenges Clinical lab leaders will work with political leaders to make the best policy choices for diagnostics.
    Khani J
    MLO Med Lab Obs; 2017 Feb; 49(2):39. PubMed ID: 30005485
    [No Abstract]   [Full Text] [Related]  

  • 30. Ensuring quality in genomic medicine: amid the rise in complex laboratory-developed tests, regulatory officials are seeking the right balance on quality assurance.
    Nelson B
    Cancer Cytopathol; 2014 Dec; 122(12):855-6. PubMed ID: 25510938
    [No Abstract]   [Full Text] [Related]  

  • 31. A call for participatory oversight.
    Terry SF
    Genet Test Mol Biomarkers; 2014 Feb; 18(2):71-2. PubMed ID: 24506510
    [No Abstract]   [Full Text] [Related]  

  • 32. Decreasing inappropriate laboratory test utilization: controlling costs and improving quality of care.
    Wilson ML
    Am J Clin Pathol; 2015 May; 143(5):614-6. PubMed ID: 25873491
    [No Abstract]   [Full Text] [Related]  

  • 33. Translation of pharmacogenetic knowledge into cancer therapeutics.
    Yong WP; Innocenti F
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):698-706. PubMed ID: 17982411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics: on the road to 'personalized medicine'.
    Woodcock J
    FDA Consum; 2005; 39(6):44. PubMed ID: 16669118
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulating laboratory-developed tests: devil will be in details.
    McNeil C
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838442
    [No Abstract]   [Full Text] [Related]  

  • 36. AABB comments on the FDA's draft guidance on considerations for early phase clinical trials for cellular therapy products.
    Cassata RK
    MLO Med Lab Obs; 2014 Oct; 46(10):40. PubMed ID: 25665247
    [No Abstract]   [Full Text] [Related]  

  • 37. A prospective tool for risk assessment of sendout testing.
    Cole B; Dickerson JA; Graber ML; Fantz CR; Laposata M; Henriksen K; Astion ML; Epner P
    Clin Chim Acta; 2014 Jul; 434():1-5. PubMed ID: 24685573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Oversight of Laboratory-Developed Tests: Where Are We Now?
    Gatter K
    Arch Pathol Lab Med; 2017 Jun; 141(6):746-748. PubMed ID: 28557601
    [No Abstract]   [Full Text] [Related]  

  • 39. Approval of novel biomarkers: FDA's perspective and major requests.
    Scherf U; Becker R; Chan M; Hojvat S
    Scand J Clin Lab Invest Suppl; 2010; 242():96-102. PubMed ID: 20515286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.